Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
NKTR-255 at 1.5 µg/kg
Nektar Therapeutics UK Limited
Non-Hodgkin Lymphoma
1 trial -
NMRA-335140
Neumora Therapeutics
Major Depressive Disorder
1 trial -
NMRA-335140
Neumora Therapeutics
Major Depressive Disorder
5 trials -
NUBEQA 300 mg film-coated tablets, Placebo to BAY1841788 film-coated tablet 300 mg
Ningbo Cancer Hospital
Localised Very High-Risk Cancer of the Prostate
1 trial -
NX-5948
Nurix Therapeutics
B-cell Lymphoma
2 trials -
NaCl 0.9%, PREDNISONE ARROW 20 mg, comprimé sécable, METHYLPREDNISOLONE , Placebo de prednisone ARW 20 mg - Hydrogénophosphate de calcium dihydraté (94%) Stéarate de magnésium (1%) Amidon de maïs Lycatab C (5%), Glucose 5%
Pari Pharma GmbH
Erythema multiforme (EM) in its severe form managed at the hospital
1 trial -
NaCl 0.9%, TRANEXAMIC ACID, TERLIPRESSIN
Pari Pharma GmbH
Hemoptysis, whatever the cause, with the exception of cystic fibrosis
1 trial -
Nab-paclitaxel 80 mg/m^2
CORCEPT THERAPEUTICS INC
Ovarian Neoplasm
1 trial -
Nalbuphine ER Tablets
Trevi Therapeutics
Prurigo Nodularis
1 trial -
Napabucasin, Bendatax 6 mg/ ml, Bendacitabin 38 mg/ml Pulver zur Herstellung einer Infusionslösung
The George Institute
Histologically or cytologically confirmed advanced pancreatic adenocarcinoma that is metastatic.
1 trial -
Natriumklorid Braun 9 mg/ml spädningsvätska för parenteral användning, COLECALCIFEROL , GRAZAX 75 000 SQ-T frystorkad sublingual tablett, Alutard SQ Timotej, 10 000 SQ-E/ml, injektionsvätska, suspension
The George Institute
Allergisk Rinit
1 trial -
Nedaplatin
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma
1 trial -
Neugranin
Teva Pharma GmbH
Chemotherapy-induced Neutropenia
1 trial -
New thickened formula
United Therapeutics Europe Ltd
Gastroesophageal Reflux
1 trial -
Newnorm
Maze Therapeutics
Human Normal Immunoglobulin
1 trial -
Niclosamide
United Therapeutics Europe Ltd
Covid19
1 trial -
Nicotine patch
Jasper Therapeutics
Nicotine Dependence
1 trial -
Nicotinomide
United Therapeutics Europe Ltd
Glaucoma, Open-Angle
1 trial -
Nimotuzumab
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma
1 trial -
Niraparib Placebo Capsules, Niraparib Placebo Tablets, G5W (5% glucose in water), JEMPERLI 500 mg concentrate for solution for infusion
TESARO Bio Netherlands B.V.
Recurrent or primary advanced (Stage III or IV) endometrial cancer
1 trial -
Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, Capivasertib, NUBEQA 300 mg film-coated tablets, CABAZITAXEL, ENZALUTAMIDE , DAROLUTAMIDE , ABIRATERONE , ABIRATERONE ACETATE, APALUTAMIDE , RADIUM (223RA) DICHLORIDE , DOCETAXEL , OLAPARIB, Capivasertib, Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, BAY 1841788
The George Institute
Prostate Cancer
1 trial -
Nivolumab
Nektar Therapeutics UK Limited
Bladder Cancer
1 trial -
Nomlabofusp, Placebo to Nomlabofusp
Larimar Therapeutics
Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein, FXN. Friedreich’s ataxia is a rare, progressive, multisystem disease with an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85.
1 trial -
Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen, Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen
NovoThirteen
Children with short stature either born small for gestational age or with Turner syndrome, Noonan syndrome, or idiopathic short stature
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources